Background: Chemotherapy is a standard strategy for stage IV gastric cancer patients. However, some cases cannot undergo conversion surgery because of their frailty, even if the patients had response to chemotherapy. For these patients, local tumor progression is a problem. We report here the case of a patient whose residual gastric cancer was resected through endoscopic submucosal dissection (ESD) after concomitant chemotherapy for metastatic gastric cancer.
Case summary: An 85-year-old male complained of difficulty swallowing, and examination revealed gastric cancer with multiple liver metastases. Although he received concomitant chemotherapy, a residual tumor was observed in the primary lesion while the metastatic lesions disappeared completely. Conversion surgery was considered optional treatment; however, he could not undergo that because of advanced age and comorbidities. Thus, we performed ESD to treat the residual tumor. As a result, we resected the residual lesion completely. The patient has been alive for 29 mo since ESD, without recurrence.
Conclusion: We achieved local control using ESD, and these findings may provide therapeutic improvements both in local control and patient survival outcomes.
Keywords: Case report; Chemotherapy; Conversion; Endoscopic submucosal dissection; Gastric cancer; Liver metastases.
Conflict of interest statement
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
[Efficacy comparison between surgical resection and endoscopic submucosal dissection of early gastric cancer in a domestic single center].Zhonghua Wei Chang Wai Ke Za Zhi. 2018 Feb 25;21(2):190-195. Zhonghua Wei Chang Wai Ke Za Zhi. 2018. PMID: 29492919 Chinese.
Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study.World J Gastroenterol. 2012 Oct 28;18(40):5799-806. doi: 10.3748/wjg.v18.i40.5799. World J Gastroenterol. 2012. PMID: 23155323 Free PMC article.
Endoscopic submucosal dissection for residual/local recurrence of early gastric cancer after endoscopic mucosal resection.Endoscopy. 2006 Oct;38(10):996-1000. doi: 10.1055/s-2006-944780. Endoscopy. 2006. PMID: 17058164
Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: a systematic review.World J Gastroenterol. 2013 Mar 7;19(9):1424-37. doi: 10.3748/wjg.v19.i9.1424. World J Gastroenterol. 2013. PMID: 23539431 Free PMC article. Review.
Colorectal endoscopic submucosal dissection: Systematic review of mid-term clinical outcomes.Dig Endosc. 2016 May;28(4):405-416. doi: 10.1111/den.12597. Epub 2016 Apr 20. Dig Endosc. 2016. PMID: 26710317 Review.
- Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. - PubMed
- Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–221. - PubMed
- Schildberg CW, Weidinger T, Hohenberger W, Wein A, Langheinrich M, Neurath M, Boxberger F. Metastatic adenocarcinomas of the stomach or esophagogastric junction (UICC stage IV) are not always a palliative situation: a retrospective analysis. World J Surg. 2014;38:419–425. - PubMed
- Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2015;26:141–148. - PubMed